How do you pay?

How to pay the least

Ask for the cash price

Darzalex Faspro

Darzalex Faspro is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

What to do

  1. Ask your pharmacy for Darzalex Faspro’s cash price, and one or two other pharmacies too.
  2. Darzalex Faspro’s savings card works only with insurance from a job or one you bought.

Other ways

Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program. Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL). Or call 1-833-742-0791.

See if you qualify 

Compare every option

Brand name

Darzalex Faspro, the original

Cash priceAsk the pharmacy
Ways to save on Darzalex Faspro

The maker’s card

J&J withMe Savings Program

Savings card from Johnson & Johnson

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $5 a dose

Sign up on jnjwithme.com 

Or call 1-833-565-9631.

In the maker’s words

“Eligible patients pay $5 for each dose.”

From the maker’s offer on jnjwithme.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

Darzalex Faspro is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

Not soldAsk the pharmacy

What it’s used for

What the FDA label says

DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with:

  • multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant
  • multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant
  • multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
  • multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
  • multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant
  • multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
  • multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor
  • multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy
  • multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent
  • high-risk smoldering multiple myeloma as monotherapy
  • light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients.

Limitations of Use:

  • DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials

Source: the FDA label for Darzalex Faspro (Janssen Biotech, Inc.), October 12, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.